Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Glaucoma Market to Grow to $3.5 Billion by 2030
According to GlobalData, the glaucoma market across the seven major markets* is predicted to grow steadily from $2.8 billion in 2020 to $3.5 billion in 2030, with a compound annual growth rate (CAGR) of 2%. According to the latest analysis…
Methylsulfonylmethane Eye Drops Contaminated, FDA Warn
The FDA has issued warning to consumers, advising them against purchasing and immediately discontinuing the use of two products: Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops – Eye Repair. The warning is based on the potential…
Oxular’s OXU-001 Receives IND Acceptence
The U.S. Food and Drug Administration has approved Oxular Limited’s investigational new drug application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND permits the OXEYE Phase 2 trial to proceed, which will assess the…
Alcon and Ivantis Lose Patent Battle to Sight Sciences.
Sight Sciences announced its success in defeating all four patent invalidity challenges that were filed against it by Alcon and Ivantis in the United States Patent and Trademark Office. Patent Infringement Litigation Over Hydrus® Microstent In September 2021, Sight Sciences…
Théa Obtains Sepofarsen and Ultevursen from ProQR
ProQR Therapeutics and Laboratoires Théa have reached an agreement through which ProQR will transfer its advanced ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will secure an initial payment totaling €12.5 million ($13.7 million).…
Oyster Pharma’s Tyrvaya Is Widely Available to Patients
Oyster Point Pharma announced the expansion of patient access to its nasal spray medication for dry eye disease, Tyrvaya (varenicline solution), and provided an update In an update on Tyrvaya’s US commercial success in the US. According to Oyster Point,…
The Biggest Challenges in Ophthalmology Today
A recent survey conducted by OBN on LinkedIn asked participants to identify the most pressing challenge facing the ophthalmology field today. The poll revealed that nearly half of the respondents believe patient access to care is the primary issue, followed…
Micro Labs Launches World’s First Triple-Drug for Glaucoma
Micro Labs, based in Bengaluru, announced the launch of Trisopt, the world’s first fixed-dose combination (FDC) to include Brimonidine, Timolol, and Brinzolamide in an ophthalmic suspension, designed specifically for the management of glaucoma. The drug is manufactured within Micro Labs’…
Global Pharma Healthcare Recalls EzriCare Eye Drops
Global Pharma Healthcare is recalling its Artificial Tears Lubricant Eye Drops due to potential contamination. The recall affects all lots within expiry and covers products distributed by EzriCare LLC and Delsam Pharma. This comes after the CDC informed the FDA…
FDA Warns of Delsam Pharma’s Artificial Eye Ointment
The FDA has issued a warning to consumers and healthcare professionals not to purchase or use Delsam Pharma’s Artificial Eye Ointment due to potential bacterial contamination. This eye oinment is an over-the-counter product, intended to be sterile and produced by…